Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Beta interferons and glatiramer acetate for treating multiple sclerosis

Tools
- Tools
+ Tools

NICE Project Team and Appraisal Committee Members (Including: Armoiry, Xavier, Auguste, Peter and Clarke, Aileen). (2018) Beta interferons and glatiramer acetate for treating multiple sclerosis. National Institute for Health and Care Excellence.

[img] PDF
WRAP-beta-interferons-and-glatiramer-acetate-for-treating-multiple-sclerosis-NICE-2018.pdf - Published Version
Embargoed item. Restricted access to Repository staff only - Requires a PDF viewer.
Available under License Available under NICE UK Open Content Licence.

Download (161Kb)
[img] PDF (Licence Statement)
NICE-UK-Open-Content-Licence-06-08-2018.pdf - Permissions Correspondence
Embargoed item. Restricted access to Repository staff only - Requires a PDF viewer.

Download (63Kb)
Official URL: https://www.nice.org.uk/guidance/ta527

Request Changes to record.

Abstract

Evidence-based recommendations on beta interferons (Avonex, Betaferon, Extavia, Rebif) and glatiramer acetate (Copaxone) for treating multiple sclerosis in adults.

This guidance replaces NICE technology appraisal guidance 32 on beta interferon and glatiramer acetate for the treatment of multiple sclerosis.

Item Type: Report
Divisions: Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences
Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School
Publisher: National Institute for Health and Care Excellence
ISBN: 9781473129825
Official Date: 27 June 2018
Dates:
DateEvent
27 June 2018Published
Status: Peer Reviewed
Publication Status: Published
Reuse Statement (publisher, data, author rights): © NICE 2018 Technology Appraisal Guidance [TA527] Beta interferons and glatiramer acetate for treating multiple sclerosis. Available from www.nice.org.uk/guidance/ta527. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights). NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
Access rights to Published version: Open Access (Creative Commons)
Copyright Holders: National Institute for Health and Care Excellence (NICE)
Date of first compliant deposit: 6 August 2018
Contributors:
ContributionNameContributor ID
Technical directorPalmer, ThomasUNSPECIFIED
Technical directorLamb, AlanUNSPECIFIED
OtherHayre, JasdeepUNSPECIFIED
Project ManagerPowell, JeremyUNSPECIFIED

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item
twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us